Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Drug

Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China

Fineline Cube Nov 19, 2024

China-based Hasten Biopharmaceutical Co., Ltd, a comprehensive biopharmaceutical company co-established by CBC Group, has announced...

Company Deals

VelaVigo and Avenzo Therapeutics Ink Global Partnership for Nectin4/TROP2 Bispecific ADC

Fineline Cube Nov 19, 2024

Shanghai-based biotech company VelaVigo, specializing in bispecific/multi-specific antibodies and antibody drug conjugates (ADCs), has announced...

Company Deals

Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments

Fineline Cube Nov 19, 2024

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered...

Company Deals

Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China

Fineline Cube Nov 18, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Deals

Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336

Fineline Cube Nov 18, 2024

Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement...

Company Drug

CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine

Fineline Cube Nov 18, 2024

China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I...

Company Deals

Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments

Fineline Cube Nov 18, 2024

Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing...

Company Deals

NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology

Fineline Cube Nov 18, 2024

China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership...

Company Deals

Shanghai’s Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design

Fineline Cube Nov 18, 2024

Matwings, an AI-based protein design service provider headquartered in Shanghai, has announced the successful completion...

Company Drug

EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment

Fineline Cube Nov 18, 2024

Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced...

Company Drug

EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC

Fineline Cube Nov 18, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Deals

Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition

Fineline Cube Nov 18, 2024

Boston Scientific Corporation (NYSE: BSX), a leading player in the medical device industry, has announced...

Company Drug

Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases

Fineline Cube Nov 18, 2024

Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...

Company Medical Device

Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong

Fineline Cube Nov 18, 2024

Peijia Medical Ltd (HKG: 9996), a leading medical device company, has announced the completion of...

Company Drug

Sanofi’s Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review

Fineline Cube Nov 18, 2024

French pharmaceutical giant Sanofi has announced that the US Food and Drug Administration (FDA) has...

Company Drug

Novo Nordisk Launches Semaglutide for Weight Management in China

Fineline Cube Nov 18, 2024

Denmark-based healthcare giant Novo Nordisk A/S (NYSE: NVO) has announced the official market launch of...

Company Drug

Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates

Fineline Cube Nov 18, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a leading biopharmaceutical company based in China, has...

Company Drug

Exegenesis Bio’s Gene Therapy EXG110 Earns Orphan Drug Status for Fabry Disease

Fineline Cube Nov 18, 2024

Exegenesis Bio, a leading provider of epigenetics experimental and analytical services headquartered in Hangzhou, has...

Company Deals

Shenzhen Weiguang Biological Partners with SUAT to Boost Life Science and Health Industry

Fineline Cube Nov 18, 2024

Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a prominent blood products manufacturer in China,...

Company Drug

Janssen-Cilag’s Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment

Fineline Cube Nov 18, 2024

Janssen-Cilag International NV, a subsidiary of the US pharmaceutical giant Johnson & Johnson (J&J; NYSE:...

Posts pagination

1 … 202 203 204 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.